Sustained reductions in hyperglycemia using a diabetes app with connected glucose meters in people with type 2 diabetes at higher risk for complications

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Aim: Assess the benefits of using a diabetes app and connected blood glucose (BG) meter in people with type 2 diabetes (PwT2D) with higher-than-recommended mean BG. It is well understood that sustained higher levels of glycemia are linked to diabetes related complications and that early intervention to reduce hyperglycemia is an important clinical goal. Methods: We sourced server data from a total population of 22,696 PwT2D using the OneTouch Reveal diabetes app in conjunction with a OneTouch Verio Flex or Reflect BG meter. We identified three groups (mean BG > 180, > 155, and between > 155 and < 180 mg/dL) at higher risk for diabetes-associated complications based on their hyperglycemia. Data from their first 14 days using the app was compared with the last 14 days at the end of each timeframe, using paired within-subject differences. Results: At 1 year in PwT2D with baseline mean BG > 155 mg/dL, readings in range (RIR) improved by 24.0%, and mean BG decreased by 35.9 mg/dL, from 196.4 mg/dL to 160.5 mg/dL. These improvements were due to reductions in hyperglycemic readings. Subjects with the highest baseline mean BG of > 180 mg/dL had the greatest reduction (–54.3 mg/dL) in mean BG after experiencing the new app and meter for 1 year. Those engaging more often with the app had greater improvements in glycemia. Conclusions: In PwT2D with higher-than-recommended mean BG, substantial improvements in glycemia were associated with subjects using a diabetes app with a connected blood glucose meter at 3 months, and these improvements were sustained out to 1-year.

Keywords

real-world evidence / diabetes app / blood glucose monitoring / digital health / connected glucose meters / readings in range / diabetes-related complications

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. Diabetes Care. 2024; 48: S128-45.

[2] Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022; 65: 1925-66.

[3] Sun S, Hisland L, Grenet G, Gueyffier F, Cornu C, Jaafari N, et al. Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: A meta-analysis of randomised control-trials. Therapies. 2022; 77: 413-23.

[4] Agrawal L, Azad N, Bahn GD, Ge L, Reaven PD, Hayward RA, et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2017; 61: 295-9.

[5] Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care. 2021; 44: 2231-7.

[6] Simonson GD, Holt EH, Grady M, Hurrell G, Gaudiani LM, Bergenstal RM. Unleashing the Potential of Blood Glucose Monitoring Data With the Ambulatory Glucose Profile Report. Clin Diabetes. 2024; 42: 550-60.

[7] Glycemic Status Assessment for Patients With Diabetes (GSD) [Internet]. National Committee for Quality Assurance (NCQA); [cited 2025 Nov 1]. Available from: https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/glycemic-status-assessment-for-patients-with-diabetes-gsd/

[8] Hu M, Le MH, Yeo YH, Wijarnpreecha K, Likhitsup A, Kim D, et al. Diabetes prevalence and management patterns in US adults, 2001-2023. Acta Diabetol. 2025; 62: 2159-70.

[9] Pantalone KM, Misra-Hebert AD, Hobbs TM, Kong SX, Ji X, Ganguly R, et al. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model. Diabetes Care. 2020; 43: 1910-9.

[10] Reed J, Dong T, Eaton E, Friswold J, Porges J, Al-Kindi SG, et al. Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial. Diabetes Obes Metab. 2024; 26: 2881-9.

[11] Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Ann Intern Med. 2017; 167: 365-74.

[12] Layne JE, Jepson LH, Carite AM, Parkin CG, Bergenstal RM. Long-Term Improvements in Glycemic Control with Dexcom CGM Use in Adults with Noninsulin-Treated Type 2 Diabetes. Diabetes Technol Ther. 2024; 26: 925-31.

[13] Grady M, Cameron H, Holt E. Sustained Improvements in Readings in-Range Using an Advanced Bluetooth^® Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from more than 55,000 People with Diabetes. Diabetes Ther. 2023; 14: 1023-35.

[14] Grady M, Warren G, Levy BL, Katz LB. Interactive Exposure With a Blood Glucose Monitor With a Novel Glucose Color Range Indicator Is Associated With Improved Glucose Range Interpretation and Awareness in Patients With Type 2 Diabetes. J Diabetes Sci Technol. 2015; 9: 841-8.

[15] Grady M, Katz LB, Levy BL. Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients With Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study). J Diabetes Sci Technol. 2018; 12: 1211-9.

[16] Grady M, Cameron H, Bhatiker A, Holt E, Schnell O. Real-World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth-Connected Blood Glucose Meter with a Mobile Diabetes Management App. Diabetes Technol Ther. 2022; 24: 770-8.

[17] Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading. Diabetes Care. 2017; 40: 994-9.

[18] Liu L, Ke W, Li H, Li F, Fan G, Kuang J, et al. Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024; 387: e080122.

[19] Gentile S, Strollo F, Viazzi F, Russo G, Piscitelli P, Ceriello A, et al. Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions. J Diabetes Res. 2018; 2018: 7153087.

[20] Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Prim Care Diabetes. 2017; 11: 3-12.

[21] Boye KS, Lage MJ, Terrell KA, Thieu VT. Therapeutic Inertia in an Insured Population with Type 2 Diabetes in the United States: A Retrospective Cohort Study. Diabetes Ther. 2025; 16: 2009-23.

[22] Grady M, MacKintosh S, Fryett M, Phillips S, Holt E. Real-World Follow-Up of People With Type 2 Diabetes Using a Mobile Diabetes App With Connected Glucose Meters Finds Improvements in Glycemia Are Durable Over 5 Years. J Diabetes Sci Technol. 2026;Epub ahead of print.

[23] Kim KJ, Choi J, Bae JH, Kim KJ, Yoo HJ, Seo JA, et al. Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study. Diabetes Metab J. 2021; 45: 368-78.